Advertisement

Topics

New Antibodies to Target the Respiratory Syncytial Virus

07:59 EST 28 Feb 2017 | Labiotech.eu

The two companies Arsanis and Adimab, both specialized in the development of monoclonal antibodies, have partnered up against respiratory syncytial virus (RSV). Their license agreement is backed by the Gates foundation. The clinical-stage biotech Arsanis is developing monoclonal antibodies (mAbs) for ...

This awesome article New Antibodies to Target the Respiratory Syncytial Virus appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: New Antibodies to Target the Respiratory Syncytial Virus

NEXT ARTICLE

More From BioPortfolio on "New Antibodies to Target the Respiratory Syncytial Virus"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...